resTORbio
resTORbio is a Boston-based, clinical-stage biopharmaceutical company developing RTB101, an oral TORC1 inhibitor for aging-related diseases, primarily Parkinson's disease. The company has since repurposed its website into a consumer beauty product review blog.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What resTORbio does
resTORbio was a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Boston, focused on developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. The company's core technology is TORC1 (target of rapamycin complex 1) inhibition, with lead candidate RTB101 — an investigational, oral, selective and potent TORC1 inhibitor that inhibits phosphorylation of multiple downstream targets. RTB101 was being developed both as monotherapy and in combination with sirolimus (another TORC1 inhibitor) to induce autophagy, with the primary clinical indication being Parkinson's disease, a neurodegenerative condition affecting approximately 7.5 million people worldwide and with a mean age at diagnosis of 70.5 years. The company was co-founded by Chen Schor (President & CEO) and David Steinberg, and was backed by investors including PureTech Health, OrbiMed, Fidelity, Nest.Bio Ventures, Quan Capital, Recharge Capital and Rock Springs Capital across roughly $115M in disclosed funding from 2017 through 2019.
The business model was structured around biopharmaceutical development and eventual commercialization, with revenue anticipated from licensing, royalties or direct sales of approved therapeutics rather than any near-term commercial product. As a clinical-stage entity, resTORbio reported $0 revenue across all reported periods (2016-2019) and generated significant operating losses consistent with R&D-heavy biotech operations. In 2019 the company advanced into clinical development with a Phase 1a/2b trial of RTB101 with or without sirolimus in Parkinson's disease patients, evaluating safety, tolerability and brain penetration.
More recently, the resTORbio.com domain has been repurposed into a consumer-facing beauty and skincare content blog covering topics such as mascara reviews, Gua Sha techniques, massage therapy and hair care product comparisons, with a linked third-party storefront. The pipeline and investor-facing materials associated with the original pharmaceutical program are no longer the primary focus of the website, indicating either a material business model pivot, asset divestiture, or operational wind-down of the original clinical-stage biopharma.
resTORbio firmographics
Firmographics- Name
- resTORbio
- Legal name
- resTORbio
- Website
- https://restorbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- resTORbio is a Boston-based, clinical-stage biopharmaceutical company developing RTB101, an oral TORC1 inhibitor for aging-related diseases, primarily Parkinson's disease. The company has since repurposed its website into a consumer beauty product review blog.
- Ownership category
- akta.pro rank
Where resTORbio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
resTORbio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Biopharmaceutical Development: The company is developing innovative medicines targeting the biology of aging to prevent or treat aging-related diseases. As a clinical-stage biopharmaceutical company, revenue would come from drug development and commercialization.
resTORbio product offering
Product offeringCore offering
resTORbio is a clinical-stage biopharmaceutical company developing oral, selective TORC1 inhibitors that target the biology of aging. Its lead candidate, RTB101, is being studied both as monotherapy and in combination with sirolimus (rapamycin) for aging-related diseases, with primary programs in Parkinson's disease and COVID-19 (PROTECTOR Phase 3). The company operates a longevity-therapeutics pipeline that translates mTOR pathway biology into investigational small-molecule drugs.
Product overview
resTORbio is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. The company's lead program is RTB101, an oral selective TORC1 inhibitor being developed alone and in combination with other TORC1 inhibitors for multiple aging-related diseases. The company is also building a pipeline of products targeting multiple mechanisms underlying the biology of aging.
Differentiator
Problem solved
Functional benefit
Products and services
- RTB101 (oral selective TORC1 inhibitor) Investigational, oral, selective, and potent TORC1 (target of rapamycin complex 1) inhibitor being developed as monotherapy and in combination with sirolimus (rapamycin) for aging-related diseases, including Parkinson's disease and COVID-19; targets clinical-stage biopharmaceutical development.
- RTB101 + sirolimus (rapamycin) combination therapy Investigational combination of resTORbio's oral selective TORC1 inhibitor RTB101 with the mTOR inhibitor sirolimus, being developed for Parkinson's disease; granted FDA Fast Track designation for the combination.
Companies that use resTORbio
Customer profileSegments1 record
Ideal customer profiles2 records
resTORbio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
resTORbio partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
resTORbio competitors and assessment
Company assessmentDirect peers
- Unity Biotechnology: Clinical-stage biotechnology company developing therapeutics that target the biology of aging, with senolytic programs in musculoskeletal and ophthalmologic indications. Directly comparable to resTORbio as a small, publicly listed aging-biology drug developer pursuing mechanism-driven interventions.
- BioAge Labs: Clinical-stage company using aging-biology discovery platforms (e.g., apelin receptor agonists) to develop therapeutics for diseases of aging. Comparable to resTORbio in translating aging biology into clinical drug candidates and in its focus on the older-adult patient population.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's. Comparable to resTORbio as a clinical-stage CNS-focused company targeting aging-related neurodegeneration, though with a broader portfolio.
- Voyager Therapeutics: Clinical-stage gene therapy company with Parkinson's disease programs targeting alpha-synuclein and other mechanisms. Comparable to resTORbio as a clinical-stage developer of disease-modifying PD therapeutics, with overlapping patient population and translational risk profile.
- CohBar: Clinical-stage biotech developing mitochondrial-derived peptides for aging-related diseases including NASH and oncology. Comparable to resTORbio as a small, publicly listed aging-biology drug developer.
Emerging players
- Insilico Medicine: AI-driven drug discovery company with an aging-biology pipeline and clinical-stage assets in fibrosis and oncology. Comparable to resTORbio as a technology-driven developer pursuing aging and age-related disease mechanisms.
- Cogent Biosciences: Clinical-stage precision therapy company with programs in aging-related and proliferative diseases. Comparable to resTORbio in stage, size, and public-company clinical biotech profile, though with different therapeutic focus.
Broad incumbents
- Calico Life Sciences: Alphabet-backed R&D organization focused on understanding the biology of aging and developing interventions for age-related diseases. Comparable to resTORbio in target disease area and aging-mechanism thesis, though with vastly greater resources.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
resTORbio social profiles
Digital presenceresTORbio financial estimates
Financial estimateRevenue estimate
Valuation estimate
resTORbio leadership team
Management profileNumber of profiles
Profiles2 records
resTORbio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
resTORbio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about resTORbio
What does resTORbio do?
resTORbio is a clinical-stage biopharmaceutical company developing oral, selective TORC1 inhibitors that target the biology of aging. Its lead candidate, RTB101, is being studied both as monotherapy and in combination with sirolimus (rapamycin) for aging-related diseases, with primary programs in Parkinson's disease and COVID-19 (PROTECTOR Phase 3). The company operates a longevity-therapeutics pipeline that translates mTOR pathway biology into investigational small-molecule drugs.
Is resTORbio a public or private company?
resTORbio is a private company. It is classified as public and is currently operating.
When was resTORbio founded?
resTORbio was founded in 2016. It employs 11 to 50 people.
Where is resTORbio based?
resTORbio is headquartered in Boston, United States, in the North America region.
How does resTORbio make money?
One revenue line is on record: biopharmaceutical Development.
Who are resTORbio's main competitors?
Direct peers on record are Unity Biotechnology, BioAge Labs, Denali Therapeutics, Voyager Therapeutics and CohBar. Emerging players are Insilico Medicine and Cogent Biosciences. Calico Life Sciences is listed as a broad incumbent.
Does resTORbio have an API?
No public API is recorded for resTORbio.